From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.

ABSTRACT: In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas. We describe the challenges associated with TMZ in clinical (drug resistance and tumor recurrence) and preclinical settings (variabilities associated with in vitro models) in treating IDH-mutant glioma. Lastly, we summarize the emerging therapeutic targets that can potentially be used in combination with TMZ.

SUBMITTER: Sun X 

PROVIDER: S-EPMC8157002 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature